CERO 0.09 CERo Therapeutics Holdings, Inc.
| Range: | 0.072-12.8 | Vol Avg: | 9997285 | Last Div: | 0 | Changes: | 0 |
| Beta: | -0.46 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Nov 30 2021 | Empoloyees: | 8 | ||
| CUSIP: | CIK: | 0001870404 | ISIN: | US71902K1051 | Country: | US | |
| CEO: | Mr. Christopher B. Ehrlich M.B.A. | Website: | https://www.cero.bio | ||||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Stock Details
Positive 0.75
CERo Therapeutics, Inc. Provides Corporate Update
Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANC...
globenewswire.com·Mon Oct 21 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow